Market Place
Sourcing Support
Cellectis Provides Financial Results for the Second Quarter 2024
06 Aug 2024 //
GLOBENEWSWIRE
FDA Grants Orphan Drug Designation To Cellectis` CLLS52 For ALL
01 Aug 2024 //
GLOBENEWSWIRE
Genzyme`s Campath (alemtuzumab) Receives Suppl Approval in the U.S.
20 May 2024 //
FDA
Genzyme`s Lemtrada (alemtuzumab) Receives Suppl Approval in the U.S.
20 May 2024 //
FDA
Genzyme`s Biologic Campath (alemtuzumab) Receives Approval in the U.S.
08 Feb 2024 //
FDA
Stem cell transplants may slow disability progression in MS
22 Dec 2022 //
EUROPEANPHARMACEUTICALREVIEW
Genzyme`s Biologic Campath (Alemtuzumab) Receives Approval in the U.S.
27 Sep 2022 //
FDA
Genzyme`s Lemtrada (alemtuzumab) Receives Approval in the U.S.
26 May 2022 //
FDA
Genzyme`s Biologic Lemtrada (Alemtuzumab) Receives Approval in the U.S.
13 Jan 2022 //
FDA
Genzyme`s Biologic Campath (Alemtuzumab) Receives Approval in the U.S.
13 Jan 2022 //
FDA
Genzyme`s Biological Alemtuzumab Receives Approval In the US
20 Aug 2021 //
FDA
Genzyme`s Campath (Alemtuzumab) Receives Supplimental Approval in US
27 Oct 2020 //
FDA
Genzyme`s Lemtrada (Alemtuzumab) Receives Supplimental Approval in US
27 Oct 2020 //
FDA
MabCampath (alemtuzumab) - Risk of Haemophagocytic Lymphohistiocytosis, Stroke
22 Jun 2020 //
FIRSTWORDPHARMA
Lemtrada (alemtuzumab): updated restrictions and strengthened monitoring
13 Feb 2020 //
GOVUK
Genzyme`s CAMPATH (Alemtuzumab) Receives Supplimental Approval in U.S
27 Nov 2019 //
FDA
Genzyme`s LEMTRADA (Alemtuzumab) Receives Supplimental Approval in U.S
27 Nov 2019 //
FDA
Sanofi settles Lemtrada dispute with Genzyme investors for $315m
04 Nov 2019 //
PMLIVE
PRAC cautions use of Lemtrada, Xeljanz in latest meeting
02 Nov 2019 //
PHARMATIMES
Genzyme’s Lemtrada (Alemtuzumab) Receives Supplemental Approval In US
29 Oct 2019 //
FDA
Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US
29 Oct 2019 //
FDA
Multiple sclerosis drug costs skyrocketed for Medicare and patients, study finds
27 Aug 2019 //
BIOPHARMADIVE
Genzyme’s Campath (Alemtuzumab) Receives Supplemental Approval In US
03 Aug 2019 //
FDA
Maia Pharms Generic Baclofen Receives Approval in US
02 Aug 2019 //
FDA
Lemtrada & serious cardiovascular and immune-mediated adverse reactions
17 May 2019 //
MHRA
Genzyme`s Campath (Alemtuzumab) Receives Approval in US
25 Apr 2019 //
FDA
Sanofi`s Lemtrada goes under EU review for fatal side effects
16 Apr 2019 //
FIERCE PHARMA
The Warren bill could promote beneficial public-private partnerships in the life sciences
22 Jan 2019 //
STAT NEWS
Genzyme`s Campath (Alemtuzumab) Receives Approval in US
16 Jan 2019 //
FDA
Bluebird’s anti-BCMA has a ‘clear lead’ in a crowded field
06 Dec 2018 //
FIERCE BIOTECH
FDA hits Sanofi`s struggling Lemtrada with new safety warning over reports
01 Dec 2018 //
FIERCE PHARMA
Genzyme`s Biological Alemtuzumab Receives Approval in US
29 Nov 2018 //
FDA
Can Sanofi`s new long-term Lemtrada data amp up MS sales?
12 Oct 2018 //
FIERCE PHARMA
Sanofi Presents 8-Year Data on Lemtrada® (Alemtuzumab)
10 Oct 2018 //
BUSINESSWIRE
Sanofi bets big on India
29 Aug 2018 //
MANUFACTURING CHEMIST
Sanofi’s internal memo after a subpoena illustrates concerns over MS drug Mkg
30 May 2018 //
STATNEWS
